DRKS00028493
Recruiting
N/A
Setting the stage for newborn screening and gene therapy: a disease-specific retrospective survey of FHL2 and 3 - FHL2/3 Study
niversitätsklinikum FreiburgCentrum für Chronische Immundefizienz (CCI)im Zentrum für Translationale Zellforschung0 sites200 target enrollmentSeptember 6, 2022
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Familial Hemophagocytic Lymphohistiocytosis 2/3
- Sponsor
- niversitätsklinikum FreiburgCentrum für Chronische Immundefizienz (CCI)im Zentrum für Translationale Zellforschung
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Genetic diagnosis of FHL2 OR FHL3
- •Initial disease manifestation and diagnosis between 2010 and 2020
Exclusion Criteria
- •lack of follow\-up data (at least alive/dead) 1 year after HSCT or diagnosis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
Establishment of expanded newborn screening system in Tokyo metropolitaSpiral Muscular Atrophy, Severe Combinede Immunodeficiency, Pompe Disease, Mucopolysaccharidosis type I &II, Fabry diseaseJPRN-UMIN000048900Department of Pediatrics, The Jikei University School of Medicine4,000
Completed
N/A
Research on newborn screening for treatable neonatal and childhood diseasesprimary immunodeficiency, spinal muscular atrophyJPRN-UMIN000045633Tokyo Medical and Dental University
Not Yet Recruiting
N/A
Genetic Newborn Screening for Rare Diseases within the Screen4Care Projectgenetic newborn screeningDRKS00033501niversitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen20,000
Recruiting
N/A
establishing newborn screening program for metabolic disorders in Udupi DistrictHealth Condition 1: null- all newborns 48 hours old also includes,doctors nurses anganwadi workersCTRI/2017/09/009912Vision Group Science and Technology
Recruiting
N/A
PAN INDIA Genetics Study of MODYHealth Condition 1: E138- Other specified diabetes mellituswith unspecified complicationsCTRI/2019/12/022394Dr V Mohan